로딩 중…
지수 로딩 중…
MYUNGIN PHARM.CO., LTD
317450· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩39,900-1.48%
2026-10-15
Financials
Valuation Metrics
MYUNGIN PHARM.CO., LTD's Market Cap is ₩5825B. Ranked #406 of 2,414 in KR market (top 17%), #270 of 781 on KOSPI (top 35%), #44 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 19%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 582.54B KRW | KR#406/2,414 Sec#44/231 |
| Revenue | 287.25B KRW | KR#848/2,414 Sec#39/231 |
| Net Income | 81.44B KRW | KR#290/2,414 Sec#19/231 |
| Total Assets | 841.67B KRW | KR#534/2,414 Sec#29/231 |
| Net Assets | 794.38B KRW | KR#350/2,414 Sec#22/231 |
| Value | ||
| P/E | 7.15x | KR#635/2,414 Sec#28/231 |
| P/B | 0.73x | KR#1,217/2,414 Sec#69/231 |
| P/S | 2.03x | KR#1,845/2,414 Sec#106/231 |
| EV/EBITDA | 5.95x | KR#336/2,414 Sec#9/231 |
| FCF Yield | 8.84% | KR#669/2,414 Sec#32/231 |
| Profitability | ||
| ROE | 10.25% | KR#591/2,414 Sec#41/231 |
| ROA | 9.68% | KR#291/2,414 Sec#23/231 |
| Op. Margin | 32.20% | KR#47/2,414 Sec#11/231 |
| Financial Health | ||
| Debt Ratio | 5.95% | KR#48/2,414 Sec#14/231 |
| Total Debt | 0 KRW | KR—/2,414 Sec—/231 |
| FCF | 51.52B KRW | KR#286/2,414 Sec#16/231 |
| Cash | 31.79B KRW | KR#977/2,414 Sec#66/231 |
| Current Ratio | 13.93x | KR#57/2,414 Sec#17/231 |
| Net Debt/EBITDA | -0.34x | KR#536/2,414 Sec#31/231 |
| Dividend | ||
| Div. Yield | 3.76% | KR#505/2,414 Sec#22/231 |
| Performance | ||
| 1Y Return | -61.71% | KR#2,212/2,414 Sec#211/231 |
| 1M Return | -7.75% | KR#1,332/2,414 Sec#133/231 |
| From 52W High | -70.33% | KR#2,114/2,414 Sec#180/231 |
| 1Y MDD | -67.35% | KR#1,844/2,414 Sec#154/231 |
| Trading | ||
| Volume | 13,665 shares | KR#1,997/2,414 Sec#196/231 |
| Trading Value | 541.4M KRW | KR#1,027/2,414 Sec#108/231 |
| Foreign Own. | 0.89% | KR#2,069/2,414 Sec#203/231 |
| Per Share | ||
| EPS | 5,578 KRW | KR#196/2,414 Sec#10/231 |
| BPS | 54,409 KRW | KR#245/2,414 Sec#14/231 |
Company Info
동사는 1985년 설립되어 유가증권시장에 상장한 중추신경계 치료 약물 전문기업임. 치매, 파킨슨, 뇌전증 등 신경계 약물과 조현병, 우울증, 불안 및 수면치료제 시장에서 국내 1위를 차지하고 있음. 일반의약품 이가탄F와 메이킨Q는 높은 인지도로 시장 선점 중이며, 원료합성부터 완제 의약품 생산까지 전 공정 기술력과 cGMP 기준 생산설비를 보유, 글로벌 제약사와 협력하고 있음. 명인제약는 1988년에 설립되었으며 경기도 화성시에 본사를 두고 있습니다.